Arcutis insider plans sale of 15,000 shares

Arcutis Biotherapeutics insider Patrick Burnett filed to sell 15,000 shares of common stock of Arcutis Biotherapeutics through Merrill Lynch on or after August 11, 2026.

Rhea-AI Filing Summary

Arcutis Biotherapeutics insider Patrick Burnett filed to sell 15,000 shares of common stock of Arcutis Biotherapeutics through Merrill Lynch on or after August 11, 2026. These shares were acquired via a stock option exercise dated January 12, 2024. In the prior three months, Burnett sold 955 shares of common stock on August 3, 2026 for $24,941.54.

Key Figures

Planned shares to be sold: 15,000 shares Acquisition date of shares: 01/12/2024 Shares sold in past 3 months: 955 shares +1 more

4 metrics

Planned shares to be sold 15,000 shares Common stock to be sold through Merrill Lynch on or after August 11, 2026

Acquisition date of shares 01/12/2024 Date of stock option exercise that generated the 15,000 shares

Shares sold in past 3 months 955 shares Common stock sold on August 3, 2026

Proceeds from recent sale $24,941.54 Total proceeds from sale of 955 shares on August 3, 2026

Key Terms

Form 144, stock option exercise, securities to be sold, securities sold during the past 3 months

4 terms

Form 144 regulatory

"Filer Information | | | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

stock option exercise financial

"Common | 01/12/2024 | Stock Option Exercise | Arcutis"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

securities to be sold regulatory

"144: Securities To Be Sold"

securities sold during the past 3 months regulatory

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ARQT insider’s Form 144 filing disclose?

The filing discloses that Patrick Burnett plans to sell 15,000 shares of Arcutis Biotherapeutics common stock, acquired via a stock option exercise on January 12, 2024, through Merrill Lynch on or after August 11, 2026.

How many Arcutis Biotherapeutics (ARQT) shares are planned for sale?

The insider plans to sell 15,000 shares of common stock. These shares are listed as securities to be sold through Merrill Lynch on or after August 11, 2026, under NASDAQ listing.

When were the ARQT shares to be sold originally acquired?

The 15,000 shares to be sold were acquired through a stock option exercise dated January 12, 2024. This links the planned sale to previously granted equity compensation in the form of stock options.

What ARQT stock sales occurred in the past three months?

In the past three months, 955 shares of Arcutis Biotherapeutics common stock were sold on August 3, 2026 for total proceeds of $24,941.54, as reported under securities sold during the past 3 months.

Who is the insider involved in the ARQT planned stock sale?

The insider is Patrick Burnett, associated with Arcutis Biotherapeutics and based in Westlake Village, California. The filing details his planned sale of 15,000 common shares and a prior sale of 955 shares for $24,941.54.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/11/2026 - 05:16 PM Accepted by SEC EDGAR 08/11/2026 - 05:16 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001741987
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Patrick Burnett
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	15000	397824	125083374	08/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/12/2024	Stock Option Exercise	Arcutis Biotherapeutics			15000	08/11/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	08/03/2026	955	24941.54

144: Remarks and Signature

Remarks
Date of Notice	08/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Patrick Burnett
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)